Shares of Nektar Therapeutics (NASDAQ:NKTR) traded down 0.7% during trading on Monday . The stock traded as low as $17.10 and last traded at $17.30, with a volume of 266,185 shares. The stock had previously closed at $17.43.

Several analysts have commented on the stock. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 2nd. Brean Capital restated a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, May 4th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and set a $17.00 price target on shares of Nektar Therapeutics in a research note on Wednesday, May 4th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $19.40.

The stock’s market capitalization is $2.37 billion. The firm’s 50-day moving average is $16.66 and its 200-day moving average is $14.67.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.03. During the same quarter in the previous year, the firm earned ($0.40) EPS. The company earned $32.77 million during the quarter, compared to analyst estimates of $34.17 million. Nektar Therapeutics’s revenue was up 44.6% compared to the same quarter last year. Equities analysts anticipate that Nektar Therapeutics will post ($1.11) EPS for the current fiscal year.

In related news, CAO Jillian B. Thomsen sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $15.09, for a total value of $1,509,000.00. Following the sale, the chief accounting officer now directly owns 106,809 shares in the company, valued at $1,611,747.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Chess sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $14.10, for a total value of $70,500.00. The disclosure for this sale can be found here.

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.